By Shania Kennedy
Mayo Clinic’s initiative to use data-derived insights to improve healthcare, Mayo Clinic Platform and data privacy company TripleBlind have announced an expanded partnership focused on de-identified data and patient privacy to improve global health outcomes.
According to the press release, healthcare systems using Mayo Clinic Platform to develop digital healthcare solutions will also have access to TripleBlind’s Privacy Builder software, which will help support secure collaboration environments and strengthen patient privacy alongside these developments.
“Mayo Clinic is a leading innovator in healthcare, and we are honored to be a fast-growing partner with the Mayo Clinic Platform [and] its digital transformation initiative… The TripleBlind Privacy Builder was created to preserve patient information and intellectual property rights,” explained TripleBlind’s co-founder and CEO, Riddhiman Das in the press release.
Under the collaboration, stakeholders will be able to analyze data without seeing, sharing, or storing it, collaborate with others without compromising patient privacy, and develop and test artificial intelligence (AI) models without exposing intellectual property using Mayo Clinic Platform_Validate.
“Mayo Clinic Platform’s vision is to create a healthier world where personalized, predictive and innovative care may be accessible to all,” said vice president of Mayo Clinic Platform product portfolio, Steve Bethke in the press release. “We’re excited to collaborate with TripleBlind to enable solution developers to _Validate their models, driving data-driven and scalable innovation in a secure environment.”
This is Mayo Clinic Platform’s latest collaboration to leverage de-identified data to bolster healthcare innovation and improve outcomes.
In June, the Platform partnered with medical technology company Becton, Dickinson and Company (BD) to utilize de-identified patient data to perform detailed post-market analysis on BD’s medical device offerings, with the goal of fueling healthcare innovation and forecasting unmet patient needs.
The partnership utilized Mayo Clinic Platform_Discover, one of the platform’s de-identified patient datasets designed to give AI developers access to large amounts of healthcare data to help them build algorithms.
From there, BD analysts examined the data, which provides information outside of what is typically gathered in medical device clinical trials, to better understand patients’ care pathways, experiences, and needs. These insights can help the company address unmet patient needs, forecast device use, and generate evidence more effectively to create better products that improve patient outcomes.
BD also hopes to use Mayo Clinic Platform data to support new claims for its products and streamline device-regulatory submissions in the future.
De-identified data is also being used to improve research into various factors that can impact health.
In January 2022, Truveta and LexisNexis launched a collaboration aimed at using de-identified data to improve the quality of health research and generate new insights into health equity.
The two organizations formed the partnership because traditional medical research does not always feature participants representative of the diversity in the US, and much of this research lacks access to key social determinants of health (SDOH) data that could help improve health equity.
Under the collaboration, the two plan to use the Truveta Platform to address these issues by linking national clinical, mortality, medical claims, and socioeconomic data using the LexisNexis Patient Centric Token, which de-identifies datasets to ensure patient privacy.
